Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients

NCT04244877 is registered in ClinicalTrials.gov with MetroHealth Medical Center as lead sponsor.

NCT NCT04244877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04244877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients
Lead sponsor
MetroHealth Medical Center
Phase
Phase 3
Overall status
Withdrawn
Start date
September 15, 2021
Completion date
December 1, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, gastrointestinal motility disorder, minimal hepatic encephalopathy, small intestinal bacterial overgrowth